# Danish drug maker Novo Nordisk has fallen behind Eli Lilly in the weight-loss drug market.

*biotech · news · 2026-04-14 · Rappler*

## Key points

- Novo Nordisk is partnering with OpenAI to integrate AI across drug discovery and operations.
- Pilot AI programs will start soon, with full integration targeted by the end of 2026.
- OpenAI will help train Novo's workforce to increase AI literacy and productivity, not replace jobs.
- Novo aims to use AI to reduce future hiring needs by boosting employee efficiency.

**Companies:** OpenAI, Novo Nordisk, Eli Lilly
**Countries:** Denmark, United Kingdom, United States

[Read the full story on Rappler](https://www.rappler.com/technology/novo-nordisk-openai-partnership-drug-development/)

---

Canonical: https://newsio.io/n/26c81f60-fb70-435f-9f48-c394e4d173aa/danish-drug-maker-novo-nordisk-has-fallen-behind-eli-lilly-in-the-weight-loss-dr
Summarized by Newsio from Rappler. https://newsio.io/how-it-works